| Drug Name |
Rasagiline |
| Drug ID |
BADD_D02441 |
| Description |
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. |
| Indications and Usage |
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa. |
| Marketing Status |
approved |
| ATC Code |
N04BD02 |
| DrugBank ID |
DB01367
|
| KEGG ID |
D08469; D10829
|
| MeSH ID |
C031967
|
| PubChem ID |
3052776
|
| TTD Drug ID |
D06OMW
|
| NDC Product Code |
16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779 |
| UNII |
003N66TS6T
|
| Synonyms |
rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect |
